In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 50 of 437

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497	Technology appraisal guidance	TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]	Technology appraisal guidance	TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]	Technology appraisal guidance	TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]	Technology appraisal guidance	TBC
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]	Technology appraisal guidance	TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]	Technology appraisal guidance	TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]	Technology appraisal guidance	TBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)	Technology appraisal guidance	TBC
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]	Technology appraisal guidance	TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297	Technology appraisal guidance	TBC
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340	Technology appraisal guidance	TBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]	Highly specialised technology	TBC
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain	Medical technologies guidance	TBC
Zio XT for detecting cardiac arrhythmias	Medical technologies guidance	TBC
Non-invasive skin closure devices for surgical incisions (MT775)	Medical technologies guidance	TBC
Surgical vessel sealing systems (MT798)	Medical technologies guidance	TBC
Managing common infections - antimicrobial prescribing guidelines	NICE guideline	TBC
Epilepsies in children, young people and adults (extraordinary review)	NICE guideline	TBC
Bipolar disorder: assessment and management (extraordinary review)	NICE guideline	TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]	Highly specialised technology	TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]	Technology appraisal guidance	TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]	Technology appraisal guidance	TBC
Peezy Midstream for urine collection (MT446)	Medical technologies guidance	TBC
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]	Technology appraisal guidance	TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]	Technology appraisal guidance	TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]	Technology appraisal guidance	TBC
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]	Technology appraisal guidance	TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]	Technology appraisal guidance	TBC
Renal cell carcinoma Pathways Pilot [ID6186]	Technology appraisal guidance	TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]	Technology appraisal guidance	TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701	Technology appraisal guidance	TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]	Technology appraisal guidance	TBC

Results per page

10
25
50
All